Search results
22 hours ago · * Idorsia measures, reports, and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business ...
22 hours ago · The trial showed statistical significance in its primary endpoint, and a second confirmatory Phase 3 study is set to commence in 2024. HyBryte™ has received Orphan Drug Designations from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), along with Fast Track status from the FDA.
22 hours ago · united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy...
22 hours ago · Updated NBTXR3 Global Development Pipeline Visualization (as of May 21, 2024) *Janssen assumed responsibility for operations in Asia after securing global rights to NBTXR3 in China and Other Asian markets from former Nanobiotix collaborator LianBio. Nanobiotix and Janssen have also aligned to intent to transfer the global sponsorship. Updated Nanobiotix corporate strategy designed to enable ...
17 hours ago · Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd today announced its financial results for the first quarter of 2024.
22 hours ago · George Ng. Chief Executive Officer. Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106. Hanover, Maryland 21076 (443) 776-3133 (Name, address, including zip code, and
